Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 882Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Stomach Neoplasms 513Esophageal Neoplasms 312Rectal Neoplasms 282Colonic Neoplasms 255Breast Neoplasms 204Neoplasms 201Liver Neoplasms 187Lung Neoplasms 175Carcinoma, Non-Small-Cell Lung 175Cholangiocarcinoma 152Ovarian Neoplasms 142Neoplasm Metastasis 137Gastrointestinal Neoplasms 134Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 99Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 55Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

tislelizumab 1nedaplatin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunotherapy Esophagus Cancer × Gastrointestinal × Clear all
NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting
93 enrolled
Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡